Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 21, 2015 1:44 PM ET

Pharmaceuticals

Company Overview of FORUM Pharmaceuticals Inc.

Company Overview

FORUM Pharmaceuticals Inc. manufactures life-changing medicines for the treatment of serious brain diseases. Its products include Gamma secretase modulation, an approach to reduce Abeta42 production; HDAC program, an activity of HDAC has an impact on brain diseases that display abnormalities in the gene transcription; PDE 10 program, an investigational phosphodiesterase inhibitor; and alpha-7 Receptor agonists, an orally administered encenicline hydrochloride. The company provides its therapies for Alzheimer's disease and Schizophrenia. The company was formerly known as EnVivo Pharmaceuticals, Inc. and changed its name to FORUM Pharmaceuticals Inc. in April, 2014. FORUM Pharmaceuticals Inc. ...

500 Arsenal Street

Watertown, MA 02472

United States

Founded in 2001

Phone:

617-225-4250

Fax:

617-225-5267

Key Executives for FORUM Pharmaceuticals Inc.

Chief Executive Officer, President and Director
Age: 51
Chief Financial Officer and Senior Vice President
Chief Scientific Officer and Senior Vice President of Research
Senior Vice President and General Counsel
Chief Medical Officer and Senior Vice President of Clinical Development
Age: 61
Compensation as of Fiscal Year 2014.

FORUM Pharmaceuticals Inc. Key Developments

FORUM Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 10:00 AM

FORUM Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 10:00 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Deborah Dunsire, Chief Executive Officer, President and Director.

FORUM Pharmaceuticals Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

FORUM Pharmaceuticals Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

FORUM Pharmaceuticals Inc. Initiates Phase 2a Clinical Trial of FRM-0334 in Frontotemporal Dementia with GRN Mutation

FORUM Pharmaceuticals Inc. announced dosing of the first patient in a Phase 2a proof of mechanism clinical trial to evaluate FORUM's investigational therapy FRM-0334 in patients with the ultra-orphan rare disease frontotemporal dementia with granulin mutation (FTD-GRN). FTD-GRN is a rare, early-onset and rapidly progressive neurodegenerative brain disorder that can affect behavior, cognition, language and motor skills. FTD-GRN results from genetic mutations in the granulin (GRN) gene that lead to less progranulin protein, which is believed to play an important role in neuron survival. FRM-0334 may have therapeutic potential to partially reverse the loss of protein function in FTD-GRN. The randomized, double-blind, placebo-controlled, dose-escalating Phase 2a clinical trial will evaluate the safety, tolerability and pharmacodynamic effects of two doses of FRM-0334 in subjects with prodromal to moderate FTD-GRN. Primary endpoints will assess the safety and tolerability of FRM-0334 in subjects with the FTD-GRN genotype, as well as effects of FRM-0334 on plasma and cerebrospinal fluid progranulin concentrations. FORUM anticipates enrolling subjects at multiple sites in the United States and Western Europe for the trial. The Company has previously completed a Phase 1 study of FRM-0334 in Europe, where it was found to be well tolerated at all doses tested.

Similar Private Companies By Industry

Company Name Region
Evergreen Licensing United States
Roxlor, LLC United States
Transition Therapeutics (USA) Inc. United States
Particle Dynamics, Inc. United States
Royal Products Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FORUM Pharmaceuticals Inc., please visit www.forumpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.